Co-infection of *Helicobacter pylori* and *Escherichia coli* in a 4-year-old child

Siamak Heidarzadeh, Javid Taghinejad, Majid Eslami, Hassan Hosseinazadegan, Abdolmajid Ghasemian

1Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
2Department of Microbiology, Malekan Branch, Islamic Azad University, Malekan, Iran
3Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
4Department of Basic science, Faculty of Medical Sciences, Maragheh, Iran

ARTICLE INFO

Article history:
Received 7 Nov 2016
Accepted 20 Nov 2016
Available online 14 Dec 2016

Keywords:
*Helicobacter pylori*  
*Escherichia coli*
Co-infection  
Pediatrics

ABSTRACT

*Helicobacter pylori* (*H. pylori*) is a colonizer of more than half population worldwide among all age groups. *Escherichia coli* (*E. coli*) isolates are also colonizers of intestinal tract and several pathovars are important because of virulence factors leading to harm to the epithelial cells. A patient co-infected by *E. coli* and *H. pylori* was detected. The ELIZA kit and conventional biochemical tests were used for detection of *H. pylori* and *E. coli*, respectively. A 4 years old girl was diagnosed for anti *H. pylori* immunoglobulin G and a high rate of *E. coli* number (10⁵ CFU/mL) was determined in the stool examination. There was no data regarding familial history of infection with *H. pylori*. This girl had a history of hospitalization in Salmas hospital. Clinical findings included: fever, diarrhea, chilling and dizziness. Co-infection of *H. pylori* and *E. coli* may complicate gastrointestinal disorders in children and if misdiagnosed or left untreated, there is the possibility of severe clinical outcomes.

1. Introduction

*Helicobacter pylori* (*H. pylori*) is a curved and spiral Gram-negative bacterium detected in the gastric and small intestine mucosa of a large proportion of humans around the world (> 50%). *H. pylori* infection is usually acquired during childhood and yet becomes chronic during adulthood if not treated[1]. Its prevalence enhances with age (cohort rather than age effect) and mainly is explained by changes in socioeconomic conditions. *H. pylori*, a heterogeneous bacterial species has pathogenic effect via several virulence factors, includes a highly pathogenic strain named *cagA* which promotes a strong inflammatory response, *vacA* which causes vacuolating of cells and activation of caspase cascade, *babA*, *subA*, *oipA* and other factors[2]. *H. pylori* infection is commonly known to lead to a number of upper digestive diseases, particularly cancer and peptic ulcer, being a degenerative disease. In fact, the peptic ulcer is a result of infection, stress, chemical irritants and also genetic susceptibility. Furthermore, *H. pylori* infection was linked to several extra-digestive disorders, such as atherosclerosis, hypertension and stroke, that all of them were associated with Alzheimer’s disease, an effect caused by impairment of the blood-brain barrier. *H. pylori* infection causes the malignant gastro-intestinal diseases such as gastric or duodenal ulcers and iron deficiency mediated anemia in children[3,4]. In addition, gastric inflammation occurs in all of patients, although *H. pylori* isolates are non-virulent and cannot penetrate the epithelial cells. The host responses mainly take place against it following the attachment of *H. pylori* to the epithelial cells of this area. The antigenic components of the bacteria are adsorbed by epithelial cells and pass the lamina propria, thus will interact and activate the B and T (mostly TH17 subtype) lymphocytes. Next, immunoglobulin G (IgG), IgA and to a lower amount IgM are produced in response to the infection. On the other hand, interleukins will be produced. Anti *H. pylori* IgG has been shown to has diagnostic use and be effective in treatment of several immune diseases especially inflammation types (gastric cancer, urticarial, lupus, kidney function, etc)[5-9]. *Escherichia coli* (*E. coli*) isolates are colonizers of intestinal tract and several pathovars are important because of virulence factors leading to harm to the epithelial cells.

2. Case presentation

Here, a 4 years old girl was diagnosed for anti *H. pylori* IgG and a high rate of *E. coli* number (10⁵ CFU/mL) was determined in the stool examination. There was no data regarding familial history of infection with *H. pylori*. The patient had been hospitalized for 2 days and no history of antibiotic consumption was found. This girl had a history of hospitalization in Salmas hospital. The clinical findings included: fever, diarrhea, chilling and dizziness. The patient was treated for *E. coli*. The antibiotic susceptibility test for *E. coli* showed that it...
was resistant to amoxicillin and cotrimoxazole, but susceptible to nitrofurantoin, ceftriaxone, amikacin, nalidixic acid, gentamycin and ciprofloxacin.

3. Discussion

There are reports of *H. pylori* infection among pediatrics population, however the role of the bacterium in the inflammation, cancer initiation and anemia have yet to be fully elucidated[10,11]. The prevalence of *H. pylori* has been determined higher in Central/South American and Asian countries and at least two-fold higher in countries with high rate of gastric cancer and increased with age in exception of Chile, Ecuador, Mexico, Japan, Latvia and Republic of Korea[12].

In this study, serum antibody against *H. pylori* specific IgA was detected in a 4 years old child. Other serum parameters were not measured. Several studies have demonstrated the relation of *H. pylori* infection and iron mediated anemia, low ferritin and haemoglobin concentration[13], growth parameters[14], recurrent abdominal pain[15], response of gastric mucosa[16], nausea, vomiting and diarrhea[17], IgG4-related non healing gastric ulcer[18] and Henoch-Schönlein purpura[19].

On the other hand, *E. coli* isolates may lead to fatal outcomes among children population. Here, we reported a child co-infected by *H. pylori* and *E. coli* exhibiting fever, diarrhea, chilling and dizziness. Although *E. coli* is a common colonizer of intestinal tract, a high number of the bacterium is important in some populations and thus there is the need for accurate antibiotic therapy.

To the best our knowledge, no previous reports have been published regarding *H. pylori* and *E. coli* co-infection among pediatrics.

The most diarrhoeic pathogens among children in developing countries are rotavirus, cryptosporidium, enterotoxigenic *E. coli* producing heat-stable toxin and *Shigella* spp.[21]. We did not determine if the isolated *E. coli* was toxigenic in this child. A systematic review uncovered that rotavirus, calicivirus and enteropathogenic and enterotoxigenic *E. coli* are the causative agents of more than half of diarrhea cases in pediatrics population under 5 years, worldwide[22].

The limitations of this study were lack of exact detection of *H. pylori* and *E. coli* and characterization of these agents, no assessment of serum parameters and drawback in history data of the patient.

Conflict of interest statement

We declare that we have no conflict of interest.

Acknowledgments

The authors acknowledge personnel of Salmas hospital for introduction of the case.

References

[1] Plummer M, Franceschi S, Vignat J, Forman D, de Martel C. Global burden of gastric cancer attributable to *Helicobacter pylori*. *Int J Cancer* 2015; 136(2): 487-90.

[2] Kamali-Sarvestani E, Bazargani A, Masoudian M, Lankarani K, Taghavi AR, Saberifiroozi M. Association of *H pylori* cagA and vacA genotypes and IL-8 gene polymorphisms with clinical outcome of infection in Iranian patients with gastrointestinal diseases. *World J Gastroenterol* 2006; 12(32): 5205-10.

[3] Taye B, Enquaselassie F, Tesfaye A, Amberbir A, Medhin G, Fogarty A, et al. Effect of early and current *Helicobacter pylori* infection on the risk of anaemia in 6.5-year-old Ethiopian children. *BMC Infect Dis* 2015; 15(1): 270.

[4] Koletzko S, Mégraud F. *Helicobacter pylori* infection in children. In: Bakertz S, Yamaoka Y, editors. *Helicobacter pylori research*. Japan: Springer; 2016, p. 443-67.

[5] Miki K. Gastric cancer screening by combined assay for serum anti-*Helicobacter pylori* IgG antibody and serum peptide antigens levels—"ABC method". *Proc Jpn Acad Ser B Phys Biol Sci* 2011; 87(7): 405-14.

[6] Tu HK, Sun LP, Gong YH, Xu Q, Long Q, Bostick R, et al. Abstract C13: Population-based evaluation of serum pepsinogen, anti-*H. pylori* IgG antibody and gastrin-17 tests for gastric cancer screening. *Cancer Prev Res* 2013; doi: 10.1158/1940-6215.

[7] Yoshimasu T, Furukawa F. Eradication therapy for urchia with high titers of anti-*H. pylori* IgG antibody. *Allergol Int* 2014; 63(1): 37-40.

[8] Kita M, Take S, Okada H, Matsushita O, Yokota K. [A study to determine the optimum antigens for the serodiagnosis of *Helicobacter Pylori* infection in Japanese patients and the association with IgG subclass and gastric cancer]. *Rinsho Byori* 2015; 63(2): 180-6. Japanese.

[9] Nasri H, Rafeian-Kopaei M. Significant association of serum *H. pylori* IgG antibody titer with kidney function in renal transplanted patients. *J Renal Inj Prev* 2013; 21(1): 23-5.

[10] Guz-Mark A, Zevit N, Morgenstern S, Shaniv R. Duodenal intraepithelial lymphocytosis is common in children without coeliac disease, and is not meaningfully influenced by *Helicobacter pylori* infection. *Aliment Pharmacol Ther* 2014; 39(11): 1314-20.

[11] Li S, Huang XL, Sui JZ, Chen SY, Xie YT, Deng Y, et al. Meta-analysis of randomized controlled trials on the efficacy of probiotics in *Helicobacter pylori* eradication therapy in children. *Eur J Pediatrics* 2014; 173(2): 153-61.

[12] Peleteteiro B, Bastos A, Ferro A, Lunet N. Prevalence of *Helicobacter pylori* infection worldwide: a systematic review of studies with national coverage. *Dig Dis Sci* 2014; 59(8): 1698-709.

[13] Queiroz DM, Harris PR, Sanderson IR, Windle HJ, Walker MM, Rocha AM, et al. Iron status and *Helicobacter pylori* infection in symptomatic children: an international multi-centered study. *PLoS One* 2013; 8(7): e68833.

[14] Dehghani SM, Karamifar H, Raeesi T, Haghhighat M. Growth parameters in children with dyspepsia symptoms and *Helicobacter pylori* infection. *Indian Pediatrics* 2013; 50(3): 324-6.

[15] Feiby GKY, Nesrin MH, Badr AM. Prevalence of *Helicobacter pylori* infection among β-thalassaemia major children with recurrent abdominal pain at Suez Canal University Hospital. *Egyt J Haematol* 2015; 40(2): 74.

[16] Margarita CP, Leopoldo M, Ezquiel FP, Javier T. Clinical consequences of *Helicobacter pylori* infection in children and its relation with the response of the gastric mucosa to the infection. *Bol Med Hosp Infant Méx* 2014; 71(1): 2-7.

[17] Dore MP, Fanciulli G, Tomasi PA, Peleteiro B, Bastos A, Ferro A, et al. Gastrintestinal symptoms and *Helicobacter pylori* infection in school-age children residing in Porto Torres, Sardinia, Italy. *Helicobacter* 2012; 17(5): 369-73.

[18] Moyer AB, Schwartz MR, Lim S, Tompsoon ML, Ro JY. IgG4-related disease in a non-healing gastric ulcer: case report. *Int J Clin Exp Pathol* 2016; 9(6): 6588-91.

[19] Xiong LJ, Mao M. Current views of the relationship between *Helicobacter pylori* and Henoch-Schönlein purpura in children. *World J Clin Pediatr* 2016; 5(1): 82-8.

[20] Taur Y, Pamer EG. The intestinal microbiota and susceptibility to infection in immunocompromised patients. *Curr Opin Infect Dis* 2013; 26(4): 3327.

[21] Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. *Lancet* 2013; 382(9888): 209-22.

[22] Lanata CF, Fischer-Walker CL, Olascoaga AC, Torres CX, Areye MJ, Black RE, et al. Global causes of diarrheal disease mortality in children <5 years of age: a systematic review. *PLoS One* 2013; 8(9): e72788.